Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb. 21, according to a ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

The F-111 Aardvark’s fuselage could lug bomb loads up to 31,000 pounds and fuel for missions up to 2,500 miles long. When the ...

Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

Aardvark Therapeutics, Inc AARD IPO will take place February, 13 on the NASDAQ exchange under the ticker AARD. The company is offering shares at an expected price between $16.00 and $18.00 per share ...

The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & ...